探索特权吡唑并[3,4- d ]嘧啶支架周围的化学空间:寻求新型的T315I突变型Abl的变构抑制剂
摘要:
具有高水平分子多样性的吡唑并[3,4- d ]嘧啶文库已通过应用允许C3,N1,C4和C6取代的合成序列开发而成。对这种基于“特权支架”的化合物集合的酶促筛选,证实了在以目标为导向的合成为特征的领域中,以多样性为导向的方法的使用。实际上,几种化合物对选定的激酶表现出高活性(即Src,Abl wt和T315I突变形式),而且有趣的是,新化合物作为A315的T315I突变形式的变构抑制剂出现了,打开了大门。开发新型非竞争性Abl抑制剂(T315I)的新机会。
探索特权吡唑并[3,4- d ]嘧啶支架周围的化学空间:寻求新型的T315I突变型Abl的变构抑制剂
摘要:
具有高水平分子多样性的吡唑并[3,4- d ]嘧啶文库已通过应用允许C3,N1,C4和C6取代的合成序列开发而成。对这种基于“特权支架”的化合物集合的酶促筛选,证实了在以目标为导向的合成为特征的领域中,以多样性为导向的方法的使用。实际上,几种化合物对选定的激酶表现出高活性(即Src,Abl wt和T315I突变形式),而且有趣的是,新化合物作为A315的T315I突变形式的变构抑制剂出现了,打开了大门。开发新型非竞争性Abl抑制剂(T315I)的新机会。
Regio- and Chemoselective Metalation of Chloropyrimidine Derivatives with TMPMgCl⋅LiCl and TMP<sub>2</sub>Zn⋅2 MgCl<sub>2</sub>⋅2 LiCl
作者:Marc Mosrin、Paul Knochel
DOI:10.1002/chem.200801831
日期:2009.1.26
Efficient zincation and magnesiation of chlorinated pyrimidines can be performed at convenient temperatures (e.g., 25 and 55 °C) by using TMPMgCl⋅LiCl and TMP2Zn⋅2 MgCl2⋅2 LiCl (TMP=2,2,6,6‐tetramethylpiperidyl) as effective bases. Quenching of the resulting zincated or magnesiated pyrimidines with various electrophiles furnishes highlyfunctionalized pyrimidines in 51–93 % yield. Oxidative aminations
A facile three-step sequence has been developed for the preparation of 1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives from 4,6-dichloro2-(methylsulfanyl)pyrimidine (DCSMP) under mild conditions. Thus, the starting material is treated with LDA to generate the 5-lithiated compound, which is then allowed to react with (het)aromatic and aliphatic aldehydes to give the corresponding 144,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-l-ols. The reaction of these compounds with primary amines in the presence of triethylamine gives 144-(alkylamino)-6-chloro-2-(methylsulfanyepyrimidin-5-yl]alkan-l-ols, of which subjection to successive treatment with an equimolar amount each of sodium hydride and ethyl chloroformate provides the desired 1,4-disubstituted 7-(methylsulfany1)-1,4-dihydro-2H-pyrimido [4,5-d] [1,3]oxazin-2-ones.
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors
Fyn is a member of the Src-family of nonreceptor protein-tyrosine kinases. Its abnormal activity has been shown to be related to various human cancers as well as to severe pathologies,; such as Alzheimer's and Parkinson's diseases. Herein, a structure-based drug design protocol was employed aimed at identifying novel Fyn inhibitors. Two hits from commercial sources (1, 2) were found active against Fyn with K-i of about 2 mu M, while derivative 4a, derived from our internal library, showed a K-i of 0.9 mu M. A hit-to-lead optimization effort was then initiated on derivative 4a to improve its potency. Slightly modifications rapidly determine an increase in the binding affinity, with the best inhibitors 4c and 44 having K(i)s of 70 and 95 nM, respectively. Both compounds were found able to inhibit the phosphorylation of : the protein Tau in an Alzheimer's model cell line and showed antiproliferative activities against different cancer cell lines.
Synthesis of 8,9-Dihydropyrimido[4,5-e][1,4]oxazepin-7(5H)-ones by the Reaction of 1-(4-Chloropyrimidin-5-yl)alkan-1-ols with N-Alkylglycines
A facile method for the construction of a new ring system, 8,9-dihydropyrimido[4,5-e][1,4]oxazepin-7(5H)-one, is described. The key feature of the synthetic route includes substitution of one of the two chloro groups of 1-(4,6-dichloropyrimidin-5-yl)alkan-1-o1 derivatives, which can easily be derived from the reaction between 5-lithiated compound of 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP) and aldehydes, with N-alkylglycines in the presence of triethylamine, followed by lactonization of the resulting hydroxy acids catalyzed by in situ generated triethylamine hydrochloride.